Observational Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026 [Associations of candidate gene polymorphisms, gut microbiota, and their interactions with NAFLD in obese children]. Wei C, Pan X, Liu Y, et al. BacteroidesCoprococcusDialisterFusicatenibacter +1 more PubMed ↗
Review FASEB journal · 2026 The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics. Zhu S, Zou M, Wu Q, et al. Akkermansia muciniphila PubMed ↗
Systematic review Current obesity reports · 2026 The Role of Butyrate in People with Metabolic Dysfunction-Associated Steatotic Liver Disease and Related Metabolic Comorbidities: A Systematic Review. González-González A, Soria-Utrilla V, Fontalba-Romero MI, et al. Faecalibacterium prausnitziiEubacterium PubMed ↗
Observational BMC microbiology · 2025 High alcohol-producing Escherichia coli causes obesity and steatotic liver disease in a non-alcoholic cohort -a preclinical study. Singh A, Singh DN, Singh AN, et al. Escherichia coli PubMed ↗
Observational Journal of translational medicine · 2025 Characterization of the gut virome in patients with nonalcoholic fatty liver disease. Wang L, Wang L, Liu M, et al. FaecalibacteriumOscillibacter PubMed ↗
Systematic review BMC gastroenterology · 2025 Therapeutic potential of Akkermansia muciniphila in non-alcoholic fatty liver disease: a systematic review. Asghari P, Ahmadi-Khorram M, Hatami A, et al. Akkermansia muciniphila PubMed ↗
Randomized trial Journal of agricultural and food chemistry · 2025 Hydroxytyrosol Improves Metabolic Dysfunction-Associated Fatty Liver Disease Dependent on the Modulation of Gut Microbiota. Xiao Y, Zhang X, Shao B, et al. Fusicatenibacter saccharivorans PubMed ↗
Observational BMC pediatrics · 2025 The association between gut microbiota and metabolic dysfunction-associated steatotic liver disease (MASLD): a case-control study. Rohani P, Shojaie S, Nikparast A, et al. CoprococcusPrevotella PubMed ↗
Review Frontiers in cellular and infection microbiology · 2025 Application of probiotic therapy in nonalcoholic fatty liver disease: mediating mechanism and future perspective. Luo XY, Huang WB, Lu CH, et al. Bifidobacterium PubMed ↗
Clinical trial Nutrition and health · 2025 Benefit of Lycium barbarum polysaccharide supplementation in patients with nonalcoholic fatty liver disease: A pre-post study. Fan Y, Pu Y, Xu X, et al. Gemmiger PubMed ↗
Meta-analysis International journal of molecular sciences · 2025 Gut Microbiota and Liver Health: Meta-Analysis of Bifidobacterium-Containing Probiotics in NAFLD Management. Chang KS, Kuo WH, Chang MH, et al. Bifidobacterium PubMed ↗
Observational The Journal of steroid biochemistry and molecular biology · 2025 Biological gender difference of bile acid metabolism in susceptibility to cholelithiasis in patients with nonalcoholic fatty liver disease. Wang Y, Deng D, Mai M, et al. EscherichiaFusobacterium PubMed ↗
Observational mSystems · 2025 Multi-omics analyses of the gut microbiota and metabolites in children with metabolic dysfunction-associated steatotic liver disease. Du L, Zhang K, Liang L, et al. [Ruminococcus] torquesAnaerostipes PubMed ↗
Randomized trial Food & function · 2025 Flaxseed powder supplementation in non-alcoholic fatty liver disease: a randomized controlled clinical trial. Tian Y, Zhou Y, Liao W, et al. EubacteriumParasutterella PubMed ↗
Review Iranian biomedical journal · 2025 Role of Gut-Liver Axis in Non-Alcoholic Fatty Liver Disease. Yaghmaei H, Taromiha A, Nojoumi SA, et al. AkkermansiaFaecalibacterium PubMed ↗
Observational Environmental health and preventive medicine · 2025 A 4-year cohort study of the effects of PNPLA3 rs738409 genotypes on liver fat and fibrosis and gut microbiota in a non-fatty liver population. Sato S, Iino C, Sasada T, et al. Blautia PubMed ↗
Observational Nutrients · 2024 Sex-Dependent Gut Microbiota Features and Functional Signatures in Metabolic Disfunction-Associated Steatotic Liver Disease. Mogna-Peláez P, Riezu-Boj JI, Milagro FI, et al. Anaerotruncus PubMed ↗
Observational BMC pediatrics · 2024 Non-alcoholic fatty liver disease and the gut microbiota in adolescents: is there a relationship? Amrousy DE, Ashry HE, Maher S, et al. BifidobacteriumClostridiumPrevotella PubMed ↗
Review World journal of gastroenterology · 2024 Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy. Guney-Coskun M, Basaranoglu M Bifidobacterium PubMed ↗
Randomized trial Nutrients · 2024 Prebiotic Treatment in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)-A Randomized Pilot Trial. Reshef N, Gophna U, Reshef L, et al. Bifidobacterium PubMed ↗
Review Probiotics and antimicrobial proteins · 2024 Gut Microbes in Polycystic Ovary Syndrome and Associated Comorbidities; Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease (CVD), and the Potential of Microbial Therapeutics. Singh V, Mahra K, Jung D, et al. AkkermansiaBilophilaFaecalibacteriumFusobacterium +2 more PubMed ↗
Systematic review Clinical nutrition · 2024 Optimal probiotic combinations for treating nonalcoholic fatty liver disease: A systematic review and network meta-analysis. Yang Y, Yang L, Wu J, et al. BifidobacteriumStreptococcus PubMed ↗
Meta-analysis PloS one · 2024 Changes in the intestinal microbiota of individuals with non-alcoholic fatty liver disease based on sequencing: An updated systematic review and meta-analysis. Cai W, Qiu T, Hu W, et al. CoprococcusEscherichiaFaecalibacteriumRuminococcus PubMed ↗
Observational Atherosclerosis · 2024 A universal plasma metabolites-derived signature predicts cardiovascular disease risk in MAFLD. Li Z, Gong R, Chu H, et al. FaecalibacteriumGemmigerParabacteroidesRuminococcus PubMed ↗
Randomized trial Food & function · 2024 Effects of dietary supplementation of fish oil plus vitamin D3 on gut microbiota and fecal metabolites, and their correlation with nonalcoholic fatty liver disease risk factors: a randomized controlled trial. Li X, Pan C, Ma W, et al. DialisterEubacterium PubMed ↗
Review Current nutrition reports · 2024 The Interplay Between Dietary Choline and Cardiometabolic Disorders: A Review of Current Evidence. Vallianou NG, Kounatidis D, Psallida S, et al. Akkermansia muciniphilaFaecalibacterium prausnitzii PubMed ↗
Review Hepatology communications · 2024 Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease. Long Q, Luo F, Li B, et al. Akkermansia muciniphilaEscherichiaFaecalibacteriumPrevotella PubMed ↗
Randomized trial Romanian journal of internal medicine = Revue roumaine de medecine interne · 2024 The effects of synbiotics on the liver steatosis, inflammation, and gut microbiome of metabolic dysfunction-associated liver disease patients-randomized trial. Mitrović M, Dobrosavljević A, Odanović O, et al. BifidobacteriumFaecalibacteriumRuminococcusStreptococcus PubMed ↗
Review Bioorganic chemistry · 2024 Effects of selenium nanoparticles produced by Lactobacillus acidophilus HN23 on lipid deposition in WRL68 cells. Lei X, Peng Y, Li Y, et al. Lactobacillus acidophilus PubMed ↗
Review Archives of microbiology · 2024 Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets. Gruzdev SK, Podoprigora IV, Gizinger OA Escherichia coliKlebsiella pneumoniae PubMed ↗
Observational Wiadomosci lekarskie · 2024 Differentiated approach to management of patients with irritable bowel syndrome and ulcerative colitis in non-alcoholic fatty liver disease. Sirchak YS, Kornash VV, Dutko OO, et al. Escherichia coliBifidobacterium PubMed ↗
Randomized trial The American journal of clinical nutrition · 2023 Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial. Chooi YC, Zhang QA, Magkos F, et al. Bifidobacterium adolescentis PubMed ↗
Meta-analysis Obesity reviews · 2023 Composition of gut microbiota and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Su X, Chen S, Liu J, et al. CoprococcusEscherichiaFusobacterium PubMed ↗
Randomized trial Cell metabolism · 2023 Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations. Ni Y, Qian L, Siliceo SL, et al. Bacteroides stercoris PubMed ↗
Review Pharmacological research · 2023 Gut mycobiome and metabolic diseases: The known, the unknown, and the future. Wang L, Zhang K, Zeng Y, et al. Saccharomyces cerevisiae PubMed ↗
Randomized trial The Journal of nutrition · 2023 Probiotic Supplementation, Hepatic Fibrosis, and the Microbiota Profile in Patients with Nonalcoholic Steatohepatitis: A Randomized Controlled Trial. Escouto GS, Port GZ, Tovo CV, et al. Bifidobacterium animalisLactobacillus acidophilus PubMed ↗
Randomized trial Frontiers in endocrinology · 2023 The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial. Hui D, Liu L, Azami NLB, et al. AlistipesBilophilaButyricimonasCoprococcus +2 more PubMed ↗
Clinical trial Gut microbes · 2023 Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis. Gómez-Pérez AM, Ruiz-Limón P, Salas-Salvadó J, et al. AkkermansiaBlautiaDesulfovibrioFaecalibacterium +1 more PubMed ↗
Observational PloS one · 2022 Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study. Tateda T, Iino C, Sasada T, et al. Blautia PubMed ↗
Clinical trial Nature communications · 2022 Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism. Lei Y, Tang L, Chen Q, et al. Clostridium PubMed ↗
Review Frontiers of medicine · 2022 Role of Akkermansia muciniphila in the development of nonalcoholic fatty liver disease: current knowledge and perspectives. Han Y, Li L, Wang B Akkermansia muciniphila PubMed ↗
Randomized trial Annals of hepatology · 2022 Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study. Barcelos STA, Silva-Sperb AS, Moraes HA, et al. Bifidobacterium animalisLacticaseibacillus paracaseiLacticaseibacillus rhamnosusLactobacillus acidophilus PubMed ↗
Review Cells · 2022 Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time? Lanthier N, Delzenne N CoprococcusEscherichiaEubacterium PubMed ↗
Observational Nutrition research · 2022 Dietary omega-6/omega-3 ratio is not associated with gut microbiota composition and disease severity in patients with nonalcoholic fatty liver disease. Heinzer K, Lang S, Farowski F, et al. Clostridium PubMed ↗
Randomized trial Nutrients · 2022 Litchi-Derived Polyphenol Alleviates Liver Steatosis and Gut Dysbiosis in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Double-Blinded, Placebo-Controlled Study. Jinato T, Chayanupatkul M, Dissayabutra T, et al. AgathobacterDialisterDoreaLachnospira +1 more PubMed ↗
Meta-analysis Journal of pediatric gastroenterology and nutrition · 2022 The Benefit of Probiotics in Pediatric Nonalcoholic Fatty Liver Disease: A Meta-analysis of Randomized Control Trials. Gkiourtzis Ν, Kalopitas G, Vadarlis A, et al. Lactobacillus acidophilusBifidobacterium PubMed ↗
Randomized trial The American journal of gastroenterology · 2022 A Freshwater Fish-Based Diet Alleviates Liver Steatosis by Modulating Gut Microbiota and Metabolites: A Clinical Randomized Controlled Trial in Chinese Participants With Nonalcoholic Fatty Liver Disease. He K, Guo LL, Tang H, et al. Faecalibacterium PubMed ↗
Randomized trial Cellular and molecular biology · 2022 Effects of Clostridium butyricum Capsules Combined with Rosuvastatin on Intestinal Flora, Lipid Metabolism, Liver Function and Inflammation in NAFLD Patients. Zhu W, Yan M, Cao H, et al. Clostridium butyricumAgathobacter rectalisBacteroides thetaiotaomicron PubMed ↗
Review Obesity reviews · 2022 Human microbiome and metabolic health: An overview of systematic reviews. Michels N, Zouiouich S, Vanderbauwhede B, et al. Akkermansia muciniphilaBacteroides fragilisBifidobacterium animalisLactiplantibacillus plantarum +7 more PubMed ↗
Observational AIDS · 2022 A pilot study of microbial signatures of liver disease in those with HIV mono-infection in Rio de Janeiro, Brazil. Yanavich C, Perazzo H, Li F, et al. Agathobacter rectalisAkkermansia muciniphilaBacteroides fragilisBacteroides stercoris +5 more PubMed ↗